Cerebrolysin vs Noopept
A side-by-side research comparison of Cerebrolysin and Noopept across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Noopept |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Noopept (GVS-111) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. |
| Molecular weight | <10,000 Da (peptide fraction) | 318.4 Da |
| Half-life | 4-6 hours | 30-60 minutes (active metabolite longer) |
| Bioavailability | High (IM/IV) | High (oral/sublingual) |
| Typical dose | 5-30 mL | 10-30 mg |
| Frequency | Daily for 10-20 days | 2-3x daily |
| Route | Intramuscular or IV | Oral or Sublingual |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
Related comparisons
Research and educational reference only. Not medical advice.